X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CADILA HEALTHCARE - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CADILA HEALTHCARE NOVARTIS/
CADILA HEALTHCARE
 
P/E (TTM) x 297.0 23.5 1,266.1% View Chart
P/BV x 25.3 5.9 429.5% View Chart
Dividend Yield % 1.4 0.8 180.5%  

Financials

 NOVARTIS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NOVARTIS
Mar-17
CADILA HEALTHCARE
Mar-17
NOVARTIS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs855460 185.9%   
Low Rs666305 218.2%   
Sales per share (Unadj.) Rs219.092.1 237.8%  
Earnings per share (Unadj.) Rs19.114.8 128.9%  
Cash flow per share (Unadj.) Rs20.318.5 109.8%  
Dividends per share (Unadj.) Rs10.003.20 312.5%  
Dividend yield (eoy) %1.30.8 157.2%  
Book value per share (Unadj.) Rs307.068.0 451.5%  
Shares outstanding (eoy) m29.961,023.74 2.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.54.2 83.6%   
Avg P/E ratio x39.825.8 154.2%  
P/CF ratio (eoy) x37.520.7 181.0%  
Price / Book Value ratio x2.55.6 44.0%  
Dividend payout %52.421.6 242.4%   
Avg Mkt Cap Rs m22,779391,581 5.8%   
No. of employees `0000.716.9 4.0%   
Total wages/salary Rs m1,39315,002 9.3%   
Avg. sales/employee Rs Th9,736.25,594.5 174.0%   
Avg. wages/employee Rs Th2,066.8890.1 232.2%   
Avg. net profit/employee Rs Th849.0899.9 94.3%   
INCOME DATA
Net Sales Rs m6,56294,295 7.0%  
Other income Rs m7021,286 54.5%   
Total revenues Rs m7,26495,581 7.6%   
Gross profit Rs m25919,036 1.4%  
Depreciation Rs m363,750 1.0%   
Interest Rs m7450 1.6%   
Profit before tax Rs m91716,122 5.7%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m3451,289 26.8%   
Profit after tax Rs m57215,168 3.8%  
Gross profit margin %3.920.2 19.5%  
Effective tax rate %37.68.0 470.5%   
Net profit margin %8.716.1 54.2%  
BALANCE SHEET DATA
Current assets Rs m9,73160,223 16.2%   
Current liabilities Rs m1,83053,058 3.4%   
Net working cap to sales %120.47.6 1,584.5%  
Current ratio x5.31.1 468.4%  
Inventory Days Days4970 69.7%  
Debtors Days Days2588 28.5%  
Net fixed assets Rs m5772,984 0.1%   
Share capital Rs m1411,024 13.7%   
"Free" reserves Rs m9,05668,576 13.2%   
Net worth Rs m9,19669,600 13.2%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m11,499152,207 7.6%  
Interest coverage x128.436.8 348.7%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.6 92.1%   
Return on assets %5.010.3 49.1%  
Return on equity %6.221.8 28.6%  
Return on capital %10.117.9 56.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12921,280 0.6%   
Fx outflow Rs m1,73410,874 15.9%   
Net fx Rs m-1,60510,406 -15.4%   
CASH FLOW
From Operations Rs m-38013,495 -2.8%  
From Investments Rs m4,208-29,103 -14.5%  
From Financial Activity Rs m-3,31823,158 -14.3%  
Net Cashflow Rs m5107,556 6.8%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.3 24.1%  
FIIs % 1.6 5.9 27.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 11.0 195.5%  
Shareholders   41,647 44,069 94.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 18, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS